Blog
RSS FeedPosted by Michael Wonder on 23 Jan 2019
Vertex’s CF drug gets label extension as pricing row continues Vertex’s CF drug gets label extension as pricing row continues
23 January 2019 - While UK cystic fibrosis patients continue their long wait for access to Vertex’s Orkambi, the drug ...
Posted by Michael Wonder on 21 Jan 2019
NHS England sees off AbbVie's hepatitis C legal challenge
21 January 2019 - Claims of unfair process dismissed by High Court. ...
Posted by Michael Wonder on 21 Jan 2019
New agreement on branded drugs for the NHS
18 January 2019 - The new Voluntary Scheme for Branded Medicines Pricing and Access began on 1 January and was ...
Posted by Michael Wonder on 18 Jan 2019
NICE OK for Bravtovi skin cancer drug
18 January 2019 - NICE has recommended Pierre Fabre’s Bravtovi (encorafenib) and Mektovi (binimetinib) combination as an option for some ...
Posted by Michael Wonder on 18 Jan 2019
Patient groups fail to declare financial interests during NICE assessments
16 January 2019 - Patients’ groups involved in assessing treatments for the NHS often fail to disclose their financial interests, ...
Posted by Michael Wonder on 18 Jan 2019
Thousands of adults with chronic lymphocytic leukaemia to benefit from new treatment option
18 January 2019 - Thousands of people will benefit as NICE recommends venetoclax with rituximab for adults with relapsed or refractory ...
Posted by Michael Wonder on 17 Jan 2019
NICE approval for Verzenios in metastatic breast cancer
17 January 2019 - NICE has recommended Eli Lilly’s Verzenios (abemaciclib) in combination with an aromatase inhibitor as treatment option ...
Posted by Michael Wonder on 16 Jan 2019
One in six Britons considers stockpiling food and medicine for Brexit
16 January 2019 - 4% of consumers already storing emergency provisions: Kantar. ...
Posted by Michael Wonder on 16 Jan 2019
The UK’s new five year pricing agreement
16 January 2019 - Pharma has agreed to capped growth again – in exchange for uptake promises. ...
Posted by Michael Wonder on 13 Jan 2019
The impact of moving from the EQ-5D-3L to the -5L in NICE technology appraisals
11 January 2019 - The EQ-5D instrument is NICE’s preferred measure of health-related quality of life in adults. ...
Posted by Michael Wonder on 10 Jan 2019
NICE publishes final guidance on another use of Keytruda for patients with NSCLC
10 January 2019 - This time it is for patients with untreated, metastatic non-squamous non-small cell lung cancer. ...
Posted by Michael Wonder on 10 Jan 2019
New migraine drug not cost-effective NICE says in draft guidance
10 January 2019 - NICE has said that a new drug for preventing migraine is not a cost effective use of ...
Posted by Michael Wonder on 09 Jan 2019
NICE publishes final guidance on the use of darvadstrocel on the NHS
9 January 2019 - The Department of Health and Social Care has asked the NICE to produce guidance on the use ...
Posted by Michael Wonder on 09 Jan 2019
Stivarga final NICE recommendation for hepatocellular carcinoma
9 January 2019 - Bayer’s Stivarga has received a final green light from NICE for use by the NHS to ...
Posted by Michael Wonder on 04 Jan 2019
Third biological treatment gives more choice for people with severe asthma
4 January 2019 - Another potentially life-changing treatment should be available to people with a severe form of asthma, NICE says. ...